Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS Q2053 (Tecartus) Fee Schedule
Last Verified: October 2026
Healthcare providers use this code to document and receive reimbursement for visits that address high-level medical decision-making, often including multiple diagnoses or prescription management.
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
| Key Fact | Detail |
|---|---|
| Service Type | Temporary Codes Other Drugs and Service Fees |
| Complexity Level | High |
| Medicaid Fee Schedule | View Medicaid rates for Q2053 |
| Medicare Payment Limit | $489304.608  |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
National average reimbursement for HCPCS Q2053 by major payers:
$311,118.74
$499,894.07
$475,367.91
$525,583.02
Compare published rates across providers.
Choose a payer to see a sample of rates for HCPCS Q2053.
HCPCS Q2053
5 of 25 sample ratesHigher to lower in this preview
Northside Hospital, Inc., Northside Hospital Gwinnett
Northside Hospital Inc
$1,235,960.00Published rateJessica Davis
Jackson Madison County General Hospital
$481,350.25Published rateSylvia Krueger
Blue Ridge Medical Oncology, PLLC
$471,240.00Published rateTeresa Lord
$449,440.00Published rateCoram Alternate Site Services, Inc.
$49,440.00Published rate
Get a free rate benchmark for your specialty.
Choose your state and specialty to build a report from payer-published rates.
Use market rates to prepare your payer proposal.
Payer Contract Negotiation
Draft a fee schedule renegotiation letter.
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS Q2053 vs. Other Other Drugs and Service Fees Codes
The HCPCS Q2053 code is part of the Temporary Codes services used for Other Drugs and Service Fees. It represents a moderate-complexity encounter and is one of several codes that vary based on time spent, level of medical decision-making, and documentation requirements.
The HCPCS Q2053 code involves more provider time and moderate medical decision-making, unlike lower-level codes that require less time and simpler assessments. It typically includes multiple diagnoses, medication management, or test interpretation, leading to higher reimbursement and more detailed documentation requirements.
| Code | Complexity | Description |
|---|---|---|
| Q2052-HCPCS | Low | Services, supplies, and accessories used in the home for the administration of intravenous immune globulin (ivig) |
| Q2053-HCPCS | High | Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
| Q2054-HCPCS | High | Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS Q2053. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the Q2053 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
FREE SAMPLE MARKET COMPARISON
Let's review your payer contracts side-by-side with the market.
Bring your top codes (like HCPCS Q2053) and we'll show you how you compare in 15 minutes or less.